Posts found in:
Grantees

Iris Bell, M.D., Ph.D.

Iris Bell, M.D., Ph.D.

Published: Jun 12, 2018   |   Author: Jen Ranieri   |   No Comments

Evaluating the Effectiveness of an Integrative Approach to the Treatment of Lymphoma and Leukemia Utilizing a Comprehensive Retrospective and Prospective Study Design Integrative Medicine is the application of additional approaches to mainstream conventional care in an integrated fashion. These approaches may include nutritional therapy, exercise, herbal medicine, spiritual healing, vitamin therapy, acupuncture, meditation, massage, and […]

Read more
Chuan He, PhD

Chuan He, PhD

Published: Jun 12, 2018   |   Author: Keisha Escoffery   |   No Comments

Improving the Efficiency of Alkylation Anticancer Chemotherapies Alkylating agents are extensively used against a number of malignancies such as lymphoma, brain tumors, melanoma and Hodgkin’s disease. These agents kill tumor cells by damaging their DNA. However, repair of the DNA damage induced by these alkylating agents by human DNA repair proteins, especially the human AGT […]

Read more
Christopher Oakes, PhD

Christopher Oakes, PhD

Published: Jun 12, 2018   |   Author: Keisha Escoffery   |   No Comments

The Role of EGR in establishing a malignant epigenetic program of therapy resistance in CLL Modification of gene structure constitutes a fundamental way healthy cells are reprogrammed into leukemia and gain therapeutic resistance. We will uncover how modifications associated with aggressive disease and relapse are created by reengineering normal cells. This will further our knowledge […]

Read more
Ingrid Karen Ruf, PhD

Ingrid Karen Ruf, PhD

Published: Jun 12, 2018   |   Author: Jen Ranieri   |   No Comments

Role of Epstein-Barr virus RNAs in the Pathogenesis of Virus-associated Lymphoid Tumors Epstein-Barr virus (EBV) infections are associated with a number of types of human cancer, including Burkitt lymphoma, nasopharyngeal carcinoma, and Hodgkin’s lymphoma. EBV carries a number of viral genes whose products are known to result in increased cell growth and/or decreased cell death, […]

Read more
Chengcheng (Alec) Zhang, PhD

Chengcheng (Alec) Zhang, PhD

Published: Jun 12, 2018   |   Author: Keisha Escoffery   |   No Comments

Ex Vivo expansion of hematopoietic stem cells for cord blood and allogeneic transplantations The ability to grow blood stem cells (HSCs) in culture would greatly improve the patient outcome in transplantation, and make cord blood to be useful for adult applications. We have identified several new growth factors, and established a very potent cell culture […]

Read more
Iannis Aifantis, PhD, BS

Iannis Aifantis, PhD, BS

Published: Jun 12, 2018   |   Author: Jen Ranieri   |   No Comments

Modeling T-Cell A.L.L. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood cancer that preferentially affects children and adolescents. The leukemia is commonly associated with specific genetic abnormalities. Dr. Aifantis’ research focuses on one particular gene, known as Notch1, which is found in more than half of T-ALL patients and which has been generally recognized […]

Read more
Boglarka Gyurkocza, MD

Boglarka Gyurkocza, MD

Published: Jun 12, 2018   |   Author: Keisha Escoffery   |   No Comments

Reducing Relapse of Acute Myeloid Leukemia after Hematopoietic Cell Transplantation We are conducting two clinical trials with novel, minimally toxic conditioning regimens – combining treosulfan or clofarabine, instead of fludarabine, with hematopoietic cell transplantation (HCT). Our goal is to reduce the incidence of recurrent leukemia following HCT, thereby increasing the likelihood of long-term survival.

Read more
Birgit Knoechel, MD, PhD

Birgit Knoechel, MD, PhD

Published: Jun 12, 2018   |   Author: Keisha Escoffery   |   No Comments

Enhancer rewiring in drug resistant T-ALL and its therapeutic implications T-cell acute lymphoblastic leukemia (T-ALL) is a disease that affects children and young adults, for which outcome has remained poor, often due to rapid development of resistance to existing therapies. We propose to determine the epigenetic alterations responsible for drug resistance in T-ALL, and develop […]

Read more
Hilda B. Ye, PhD

Hilda B. Ye, PhD

Published: Jun 12, 2018   |   Author: Jen Ranieri   |   No Comments

The Role of BCL-6 Regulated Chemokine Expression in the Pathogenesis of B-Cell Lymphomas Non-Hodgkin’s lymphoma (NHL) is the most common form of lymphoid malignancy in the adult population. Despite the advent of new drugs and treatment regimens, only 50% of NHL patients are cured, calling for the need of better understanding of the pathogenesis of […]

Read more